Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 52%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Medline Inc. demonstrated robust financial performance in fiscal year 2024, with Supply Chain Solutions generating $13 billion in revenue, reflecting a 12% year-over-year increase and accounting for 51% of total revenues. The company's adjusted EBITDA reached $3.4 billion, marking a 21% year-over-year growth and a corporate-wide EBITDA margin of 13.2%. Medline's consistent revenue growth during economic downturns, evidenced by a 17% CAGR during the 2008-2009 financial crisis and an 11% CAGR during COVID-19, underscores the resilience and demand stability of its medical-surgical products and supply chain solutions.

Bears say

The financial outlook for Medline Inc appears negative due to several fundamental reasons. Firstly, the healthcare sector is experiencing significant challenges, including low margins exacerbated by inflation, staffing shortages, and reduced patient volumes due to fewer insured individuals, which could lead to constrained revenue growth. Additionally, Medline's existing debt load may limit its capacity for mergers and acquisitions, hindering potential top-line growth opportunities, while increased competition for key customers poses further risks to revenue and earnings stability.

Medline Inc (MDLN) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 52% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 23 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Feb 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.74, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.74, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.